Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 2Efficacy & side effects

3(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(1)

Detailed Status

Completed2

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 23 (100.0%)

Trials by Status

completed267%

withdrawn133%

Recent Activity

0 active trials

Showing 3 of 3

withdrawnphase_2

A Safety and Efficacy Study of Intranasal GSK2245035 in Adults With Allergic Asthma

NCT03707678

completedphase_2

A Study to Investigate the Safety and Pharmacodynamics of Repeat Intranasal Administration of the TLR7 Agonist GSK2245035 in Subjects With Respiratory Allergies

NCT01607372

completedphase_2

To Investigate the Safety, Pharmacodynamics and Effect on Allergic Reactivity of the Toll-like Receptor 7 (TLR7) Agonist GSK2245035 in Subjects With Respiratory Allergies

NCT01788813

Clinical Trials (3)

Showing 3 of 3 trials

NCT03707678Phase 2

A Safety and Efficacy Study of Intranasal GSK2245035 in Adults With Allergic Asthma

Withdrawn

NCT01607372Phase 2

A Study to Investigate the Safety and Pharmacodynamics of Repeat Intranasal Administration of the TLR7 Agonist GSK2245035 in Subjects With Respiratory Allergies

Completed

NCT01788813Phase 2

To Investigate the Safety, Pharmacodynamics and Effect on Allergic Reactivity of the Toll-like Receptor 7 (TLR7) Agonist GSK2245035 in Subjects With Respiratory Allergies

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3